Summit Therapeutics Inc. Adjustments For Finance Costs
Summit Therapeutics Inc. (SMMT) reported Adjustments For Finance Costs of GBP 52.00 thousand for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForFinanceCosts · last filed 2020-06-02
- Summit Therapeutics Inc. adjustments for finance costs for the quarter ending 2020-03-31 was 52.00K GBP, a 14.75% decline year-over-year.
- Summit Therapeutics Inc. adjustments for finance costs for the quarter ending 2019-10-31 was 63.00K GBP, a 5.00% increase year-over-year.
- Summit Therapeutics Inc. adjustments for finance costs for the quarter ending 2019-07-31 was 62.00K GBP, a 58.67% decline year-over-year.
- Summit Therapeutics Inc. adjustments for finance costs for the quarter ending 2019-04-30 was 61.00K GBP, a 69.50% decline year-over-year.
| Period end | Adjustments For Finance Costs 3 month | Adjustments For Finance Costs 3 month as first filed | Adjustments For Finance Costs 6 month | Adjustments For Finance Costs 6 month as first filed | Adjustments For Finance Costs 9 month | Adjustments For Finance Costs 9 month as first filed | Adjustments For Finance Costs 11 month | Adjustments For Finance Costs 12 month | Adjustments For Finance Costs 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | 52.00K GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-12-31 | 228.00K GBP 20-F · filed 2020-04-30 | ||||||||
| 2019-10-31 | 63.00K GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | 125.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | 186.00K GBP 6-K · filed 2019-12-17 | ||||||
| 2019-07-31 | 62.00K GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | 123.00K GBP 6-K · filed 2019-10-11 | |||||||
| 2019-04-30 | 61.00K GBP 6-K · filed 2019-06-12 | ||||||||
| 2019-03-31 | 60.00K GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-01-31 | 57.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 117.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 267.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 467.00K GBP 20-F · filed 2020-04-30 | 424.00K GBP 20-F · filed 2019-03-29 | ||||
| 2018-10-31 | 60.00K GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | 210.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | 410.00K GBP 6-K · filed 2019-12-17 | 377.00K GBP 6-K · filed 2018-12-11 | 929.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-07-31 | 150.00K GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | 350.00K GBP 6-K · filed 2019-10-11 | 328.00K GBP 6-K · filed 2018-09-20 | 869.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 1.09M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-04-30 | 200.00K GBP 6-K · filed 2019-06-12 | 188.00K GBP 6-K · filed 2018-06-05 | 719.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 944.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 1.16M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-01-31 | 519.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 744.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 963.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 1.19M GBP 20-F · filed 2020-04-30 | 1.16M GBP 20-F · filed 2018-04-13 | ||||
| 2017-10-31 | 225.00K GBP derived: 6-K 9 month − 6-K 6 month · filed 2018-12-11 | 444.00K GBP derived: sum of 2 quarters · filed 2018-12-11 | 668.00K GBP 6-K · filed 2018-12-11 | ||||||
| 2017-07-31 | 219.00K GBP derived: 6-K 6 month − 6-K 3 month · filed 2018-09-20 | 443.00K GBP 6-K · filed 2018-09-20 | |||||||
| 2017-04-30 | 224.00K GBP 6-K · filed 2018-06-05 | ||||||||
| 2017-01-31 | 862.00K GBP 20-F · filed 2019-03-29 | ||||||||
| 2016-01-31 | 2.88M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |